Dataset Information

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

ABSTRACT: During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

SUBMITTER: Ludwig H

PROVIDER: S-EPMC6035147 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig Heinz H Delforge Michel M Facon Thierry T Einsele Hermann H Gay Francesca F Moreau Philippe P Avet-Loiseau Hervé H Boccadoro Mario M Hajek Roman R Mohty Mohamad M Cavo Michele M Dimopoulos Meletios A MA San-Miguel Jesús F JF Terpos Evangelos E Zweegman Sonja S Garderet Laurent L Mateos María-Victoria MV Cook Gordon G Leleu Xavier X Goldschmidt Hartmut H Jackson Graham G Kaiser Martin M Weisel Katja K van de Donk Niels W C J NWCJ Waage Anders A Beksac Meral M Mellqvist Ulf H UH Engelhardt Monika M Caers Jo J Driessen Christoph C Bladé Joan J Sonneveld Pieter P

Leukemia 20180502 7

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give p ...[more]

PMID: 29720735

Similar Datasets

Project description:High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the Revised International Staging System (R-ISS) which was set up in 2015. Since then, new clinical and biological prognostic factors have been developed, which could implement the definition of High Risk (HR) category. We conducted a survey in order to identify which additional parameters, both clinical and biological, are considered more useful for the clinical practice and to evaluate if the management of Multiple Myeloma (MM) should change on the basis of the risk category. A questionnaire, consisting of 8 statements, was submitted to 6 Italian experts, from the European Myeloma Network (EMN) Research Italy, using the Delphi method. The colleagues were asked to answer each question using a scale between 0 and 100. If a statement did not reach at least 75 out of 100 points from all the participants, it was rephrased on the basis of the proposal of the experts and resubmitted in a second or further round, until a consensus was reached among all. From the first round of the survey a strong consensus was reached regarding the opportunity to revise the R-ISS including chromosome 1 abnormality, TP53 mutation or deletion, circulating plasma cells by next generation flow and extramedullary plasmacytomas. No consensus was reached for the definition of "double hit" MM and for the application in clinical practice of treatment strategies based on the risk category. In the second round of the Delphi questionnaire, "double-hit" MM was recognized by the association of at least two high-risk cytogenetic or molecular abnormalities. Moreover, the experts agreed to reserve an intensified treatment only to specific conditions, such as plasma cell leukaemia or patients with multiple extramedullary plasmacytomas, while they admitted that there are not sufficient real word data in order to modify treatment on the basis of MRD assessment in clinical practice. This survey suggests that the definition of HRMM should be implemented by additional clinical and biological risk factors, that will be useful to guide treatment in the future.

Dataset Information

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Publications

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets